期刊文献+

Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care 被引量:1

Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care
下载PDF
导出
摘要 Despite a high prevalence of hepatitis C virus(HCV)infection,the vast majority of persons who inject drugs(PWID)have not engaged in HCV care due to a large number of obstacles.Education about the infection among both PWID and providers remains an important challenge as does discrimination faced by PWID in conventional health care settings.Many providers also remain hesitant to prescribe antiviral therapy due to concerns about adherence and relapse to drug use resulting in reinfection.Presently,however,as a result of improvements in treatment efficacy combined with professional society and government endorsement of HCV treatment for PWID,a pressing need exists to develop strategies to engage these individuals into HCV care.In this article,we propose several strategies that can be pursued in an attempt to engage PWID into HCV management.We advocate that multidisciplinary approaches that utilize health care practitioners from a wide range of specialties,as well as co-localization of medical services,are strategies likely to result in increased numbers of PWID entering into HCV management.Pursuit of HCV therapy after stabilization through drug treatment is an additional strategy likely to increase PWID engagement into HCV care.The full impact of direct acting antivirals for HCV will only be realized if innovative approaches are pursued to engage all HCV infected individuals into treatment. Despite a high prevalence of hepatitis C virus (HCV) infection, the vast majority of persons who inject drugs (PWID) have not engaged in HCV care due to a large number of obstacles. Education about the infection among both PWID and providers remains an important challenge as does discrimination faced by PWID in conventional health care settings. Many providers also remain hesitant to prescribe antiviral therapy due to concerns about adherence and relapse to drug use resulting in reinfection. Presently, however, as a result of improvements in treatment efficacy combined with professional society and government endorsement of HCV treatment for PWID, a pressing need exists to develop strategies to engage these individuals into HCV care. In this article, we propose several strategies that can be pursued in an attempt to engage PWID into HCV management. We advocate that multidisciplinary approaches that utilize health care practitioners from a wide range of specialties, as well as co-localization of medical services, are strategies likely to result in increased numbers of PWID entering into HCV management. Pursuit of HCV therapy after stabilization through drug treatment is an additional strategy likely to increase PWID engagement into HCV care. The full impact of direct acting antivirals for HCV will only be realized if innovative approaches are pursued to engage all HCV infected individuals into treatment.
出处 《World Journal of Gastroenterology》 SCIE CAS 2013年第44期7846-7851,共6页 世界胃肠病学杂志(英文版)
关键词 TREATMENT of HEPATITIS C Viral infection Human immunodeficiency VIRUS HEPATITIS C VIRUS coinfection PERSONS WHO inject DRUGS Obstacles to TREATMENT Treatment of hepatitis C Viral infection Human immunodeficiency virus Hepatitis C virus coinfection Persons who inject drugs Obstacles to treatment
  • 相关文献

参考文献53

  • 1Bart P. Grady,Janke Schinkel,Xiomara V. Thomas,Olav Dalgard.Hepatitis C Virus Reinfection Following Treatment Among People Who Use Drugs[J]. Clinical Infectious Diseases . 2013 (suppl 2)
  • 2Geert Robaeys,Jason Grebely,Stefan Mauss,Philip Bruggmann,Joseph Moussalli,Andrea De Gottardi,Tracy Swan,Amber Arain,Achim Kautz,Heino St?ver,Heiner Wedemeyer,Martin Schaefer,Lynn Taylor,Markus Backmund,Olav Dalgard,Maria Prins,Gregory J. Dore.Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs[J]. Clinical Infectious Diseases . 2013 (suppl 2)
  • 3Esther J. Aspinall,Stephen Corson,Joseph S. Doyle,Jason Grebely,Sharon J. Hutchinson,Gregory J. Dore,David J. Goldberg,Margaret E. Hellard.Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis[J]. Clinical Infectious Diseases . 2013 (suppl 2)
  • 4K. Bichoupan,V. Martel-Laferriere,M. Ng,E.A. Schonfeld,A. Pappas,J. Crismale,A. Stivala,V. Khaitova,D. Gardenier,P. Perumalswami,T.D. Schiano,J.A. Odin,L. Liu,D.T. Dieterich,A.D. Branch.795 REAL WORLD COSTS OF TELAPREVIR-BASED TRIPLE THERAPY, INCLUDING COSTS OF MANAGING ADVERSE EVENTS, AT THE MOUNT SINAI MEDICAL CENTER, NY: $147,000 PER EOT[J]. Journal of Hepatology . 2013
  • 5Edmund J. Bini,Steven Kritz,Lawrence S. Brown,Jim Robinson,Donald Calsyn,Don Alderson,Kathlene Tracy,Patrick McAuliffe,Cheryl Smith,John Rotrosen.Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States[J]. Journal of Substance Abuse Treatment . 2012 (4)
  • 6Joseph Moussalli,Helene Delaquaize,Dominique Boubilley,Jean Pierre Lhomme,Jules Merleau Ponty,David Sabot,Anne Kerever,Marc Valleur,Thierry Poynard,Karel R. Geboes.Factors to Improve the Management of Hepatitis C in Drug Users: An Observational Study in an Addiction Centre[J]. Gastroenterology Research and Practice . 2010
  • 7Gary L. Davis,Miriam J. Alter,Hashem El–Serag,Thierry Poynard,Linda W. Jennings.Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression[J]. Gastroenterology . 2010 (2)
  • 8Natasha K. Martin,Peter Vickerman,Graham R. Foster,Sharon J. Hutchinson,David J. Goldberg,Matthew Hickman.Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility[J]. Journal of Hepatology . 2010 (6)
  • 9Alain H. Litwin,Kenneth A. Harris,Shadi Nahvi,Philippe J. Zamor,Irene J. Soloway,Peter L. Tenore,Daniel Kaswan,Marc. N. Gourevitch,Julia H. Arnsten.Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program[J]. Journal of Substance Abuse Treatment . 2009 (1)
  • 10Shruti H. Mehta,Becky L. Genberg,Jacquie Astemborski,Ravi Kavasery,Gregory D. Kirk,David Vlahov,Steffanie A. Strathdee,David L. Thomas.Limited Uptake of Hepatitis C Treatment Among Injection Drug Users[J]. Journal of Community Health . 2008 (3)

同被引文献58

  • 1Hashem B. El-Serag.Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma[J]. Gastroenterology . 2012 (6)
  • 2Hashem B. El-serag,Thomas Tran,James E. Everhart.Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma[J].Gastroenterology.2004(2)
  • 3El-Serag HB.Hepatocellular carcinoma. The New England Journal of Medicine . 2011
  • 4Schütte K,Schulz C,Poranzke J,et al.Characterization and prognosis of patients with hepatocellular carcinoma (HCC)in the non-cirrhotic liver. BMC Gastroenterology . 2014
  • 5Smith Benjamin D,Smith Grace L,Hurria Arti,Hortobagyi Gabriel N,Buchholz Thomas A.Future of cancer incidence in the United States: burdens upon an aging, changing nation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology . 2009
  • 6Jacques Ferlay,Isabelle Soerjomataram,Rajesh Dikshit,Sultan Eser,Colin Mathers,Marise Rebelo,Donald Maxwell Parkin,David Forman,Freddie Bray.SJWD14121600000297[J]. Int. J. Cancer . 2015 (5)
  • 7H.Kuper,H.‐O.Adami,D.Trichopoulos.??Infections as a major preventable cause of human cancer(J)Journal of Internal Medicine . 2001 (3)
  • 8Basile Njei,Yaron Rotman,Ivo Ditah,Joseph K. Lim.??Emerging trends in hepatocellular carcinoma incidence and mortality(J)Hepatology . 2015 (1)
  • 9Hashem B. El–Serag,Howard Hampel,Fariba Javadi.??The Association Between Diabetes and Hepatocellular Carcinoma: A Systematic Review of Epidemiologic Evidence(J)Clinical Gastroenterology and Hepatology . 2006 (3)
  • 10Ryerson AB,Eheman CR,Altekruse SF,Ward JW,Jemal A,Sherman RL,Henley SJ,Holtzman D,Lake A,Noone AM,Anderson RN,Ma J,Ly KN,Cronin KA,Penberthy L,Kohler BA.Annual Report to the Nation on the Status of Cancer,1975-2012,featuring the increasing incidence of liver cancer. Cancer . 2016

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部